WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2014189393) BIOACTIVE COMPOUNDS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2014/189393    International Application No.:    PCT/NZ2014/000096
Publication Date: 27.11.2014 International Filing Date: 26.05.2014
IPC:
C07D 487/22 (2006.01)
Applicants: HAMPTON, Mark Barry [NZ/NZ]; (NZ).
SELWOOD, Andrew Ian [NZ/NZ]; (NZ).
SHI, Feng [CN/AU]; (AU)
Inventors: HAMPTON, Mark Barry; (NZ).
SELWOOD, Andrew Ian; (NZ).
SHI, Feng; (AU)
Agent: PARKER, Stephen Robert; (NZ)
Priority Data:
611064 24.05.2013 NZ (Priority Withdrawn 20.11.2015)
611061 24.05.2013 NZ (Priority Withdrawn 20.11.2015)
Title (EN) BIOACTIVE COMPOUNDS
(FR) COMPOSÉS BIOACTIFS
Abstract: front page image
(EN)The invention relates to novel bioactive polycyclic ether compounds comprising a spiro-linked five-membered cyclic imine. In particular, the invention relates to a compound designated portimine, its congeners and the use of these compounds in anticancer therapy. In a second aspect the invention provides a pharmaceutical preparation comprising as active ingredient a congener of the first aspect of the invention. Preferably, the pharmaceutical preparation is indicated for use in the treatment of subjects with neoplasia. More preferably, the pharmaceutical preparation is indicated for use in the treatment of subjects with lymphoid malignancies. Preferably, the lymphoid malignancies are selected from the group consisting of: chronic lymphocytic leukaemia (CLL) and pediatric acute lymphoblastic leukaemia (ALL).
(FR)L'invention concerne de nouveaux composés éther polycyclique bioactifs comprenant une imine cyclique à cinq chaînons à liaison spiro. En particulier, l'invention concerne un composé appelé portimine, ses congénères, et l'utilisation de ces composés dans une thérapie anticancéreuse.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)